We will have limited operations from 15:00 Tuesday 24 December 2024 (AEDT) until Thursday 2 January 2025. Find out how to contact us during the holiday period.

Appendix 1 - Financial performance by industry sector group

Version 2.0, November 2021

Last updated

30 November 2021

1. Prescription medicines
Revenue and expenses	2016-17 Actual $'m	2017-18 Actual $'m	2018-19 Actual $'m	2019-20 Actual $'m	2020-21 Actual $'m
Cost recovery revenue	68.5	72.9	74.8	80.6	88.0
Total A	68.5	72.9	74.8	80.6	88.0
Direct	40.0	39.4	41.5	44.6	48.0
Indirect	28.3	28.8	30.4	30.7	30.3
Total B	68.4	68.2	71.9	75.3	78.3
Surplus (deficit)	0.1	4.7	2.9	5.3	9.7

2. Over the counter medicines
Revenue and expenses	2016-17 Actual $'m	2017-18 Actual $'m	2018-19 Actual $'m	2019-20 Actual $'m	2020-21 Actual $'m
Cost recovery revenue	7.8	9.0	10.3	9.9	8.57
Total A	7.8	9.0	10.3	9.9	8.57
Direct	3.0	2.9	3.7	4.2	4.43
Indirect	2.6	2.4	3.0	3.2	3.31
Total B	5.7	5.3	6.7	7.4	7.74
Surplus (deficit)	2.1	3.7	3.6	2.5	0.83

3. Complementary medicines
Revenue and expenses	2016-17 Actual $'m	2017-18 Actual $'m	2018-19 Actual $'m	2019-20 Actual $'m	2020-21 Actual $'m
Cost recovery revenue	13.8	14.5	15.1	16.6	17.9
Total A	13.8	14.5	15.1	16.6	17.9
Direct	7.3	6.9	10.2	11.2	10.8
Indirect	5.6	5.3	7.6	8.5	8.3
Total B	12.9	12.1	17.8	19.7	19.1
Surplus (deficit)	0.9	2.4	(2.7)	(3.1)	(1.2)

4. Medical devices, including in-vitro diagnostic (IVD) devices
Revenue and expenses	2016-17 Actual $'m	2017-18 Actual $'m	2018-19 Actual $'m	2019-20 Actual $'m	2020-21 Actual $'m
Cost recovery revenue	37.2	40.6	41.1	46.3	45.5
Total A	37.2	40.6	41.1	46.3	45.5
Direct	19.6	20.6	22.0	26.6	31.5
Indirect	13.8	16.9	18.2	17.4	18.6
Total B	33.3	37.6	40.2	44.0	50.1
Surplus (deficit)	3.9	3.0	0.9	2.3	(4.6)

5. Good manufacturing practices
Revenue and expenses	2016-17 Actual $'m	2017-18 Actual $'m	2018-19 Actual $'m	2019-20 Actual $'m	2020-21 Actual $'m
Cost recovery revenue	9.9	13.2	12.4	15.2	15.8
Total A	9.9	13.2	12.4	15.2	15.8
Direct	8.7	8.8	8.6	8.9	8.8
Indirect	5.7	6.2	5.9	6.9	6.8
Total B	14.4	14.9	14.5	15.8	15.6
Surplus (deficit)	(4.5)	(1.7)	(2.1)	(0.6)	0.2

6. Blood, blood components and biologicals
Revenue and expenses	2016-17 Actual $'m	2017-18 Actual $'m	2018-19 Actual $'m	2019-20 Actual $'m	2020-21 Actual $'m
Cost recovery revenue	2.6	2.4	2.7	2.7	2.8
Total A	2.6	2.4	2.7	2.7	2.8
Direct	2.0	2.0	2.3	2.6	2.8
Indirect	1.6	1.7	1.9	1.8	2.0
Total B	3.6	3.6	4.2	4.4	4.8
Surplus (deficit)	(1)	(1.2)	(1.5)	(1.7)	(2.0)

7. Other activities (such as laboratory, medicines and chemical scheduling etc.)
Revenue and expenses	2016-17 Actual $'m	2017-18 Actual $'m	2018-19 Actual $'m	2019-20 Actual $'m	2020-21 Actual $'m
Revenue	1.7	2.7	4.9	5.1	6.4
Total A	1.7	2.7	4.9	5.1	6.4
Other Expense	2.7	2.6	4.9	4.5	4.2
MMDR Expense	6.9	4.1	N/A		3.3
Total B	8.6	6.7	4.9	4.5	7.5
Surplus (deficit)	(6.9)	(4.0)	0.0	0.6	(1.1)